# NCT03728556 (NCT03728556)

> A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03728556
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: CStone Pharmaceuticals
- Conditions: Non-Small Cell Lung Cancer Stage III
- Interventions: CS1001 monoclonal antibody; CS1001 placebo
- Enrollment: 381
- Primary outcome: Progress Free Survival (PFS)

## Indexed commentary on NCT03728556 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03728556
